ResMed Stock Price, News & Analysis (NYSE:RMD)

$85.84 -0.60 (-0.69 %)
(As of 12/13/2017 01:57 AM ET)
Previous Close$86.44
Today's Range$85.28 - $86.70
52-Week Range$60.13 - $87.81
Volume493,200 shs
Average Volume846,984 shs
Market Capitalization$12.26 billion
P/E Ratio30.09
Dividend Yield1.62%

About ResMed (NYSE:RMD)

ResMed logoResMed Inc. is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases. SDB includes obstructive sleep apnea (OSA) and other respiratory disorders that occur during sleep. Its cloud-based software digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes. The Company's portfolio of products includes devices, diagnostic products, mask systems, headgear and other accessories, dental devices, portable oxygen concentrators (POCs) and cloud-based software informatics solutions. The Company produces Continuous Positive Airway Pressure (CPAP), Variable Positive Airway Pressure (VPAP) and AutoSet systems for the titration and treatment of SDB.

Receive RMD News and Ratings via Email

Sign-up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryHealth Care Equipment


Debt-to-Equity Ratio0.50%
Current Ratio4.72%
Quick Ratio3.86%


Trailing P/E Ratio30.09
Forward P/E Ratio28.61
P/E Growth1.92

Sales & Book Value

Annual Sales$2.07 billion
Price / Sales5.89
Cash Flow$3.60 per share
Price / Cash23.86
Book Value$13.82 per share
Price / Book6.21


Trailing EPS$2.47
Net Income$342.28 million
Net Margins16.58%
Return on Equity21.53%
Return on Assets11.90%


Outstanding Shares141,900,000

ResMed (NYSE:RMD) Frequently Asked Questions

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed announced a quarterly dividend on Thursday, October 26th. Shareholders of record on Thursday, November 9th will be given a dividend of $0.35 per share on Thursday, December 14th. This represents a $1.40 annualized dividend and a yield of 1.63%. The ex-dividend date is Wednesday, November 8th. View ResMed's Dividend History.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) announced its earnings results on Thursday, October, 26th. The medical equipment provider reported $0.66 EPS for the quarter, meeting the Thomson Reuters' consensus estimate of $0.66. The medical equipment provider earned $523.66 million during the quarter, compared to analyst estimates of $506.08 million. ResMed had a net margin of 16.58% and a return on equity of 21.53%. The firm's revenue was up 12.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.62 earnings per share. View ResMed's Earnings History.

When will ResMed make its next earnings announcement?

ResMed is scheduled to release their next quarterly earnings announcement on Monday, January, 22nd 2018. View Earnings Estimates for ResMed.

Where is ResMed's stock going? Where will ResMed's stock price be in 2017?

11 analysts have issued 12 month target prices for ResMed's stock. Their forecasts range from $55.00 to $82.00. On average, they expect ResMed's stock price to reach $65.83 in the next year. View Analyst Ratings for ResMed.

What are Wall Street analysts saying about ResMed stock?

Here are some recent quotes from research analysts about ResMed stock:

  • 1. According to Zacks Investment Research, "ResMed exited the first quarter fiscal 2018 on a promising note with better-than-expected earnings and revenue performances. The company achieved solid double-digit global revenue growth this quarter, led by sales from Software-as-a-Service businesses as well as its new mask products and devices. We are encouraged to note that the company is working on product innovation through extensive research and development. The company also recently launched the AirFit N20 Classic nasal mask for positive airway pressure (PAP) treatment in Europe. In the past six months, ResMed has traded above the broader industry. However, challenges like competitive bidding and reimbursement issues continue to plague the stock. The company also remains exposed to foreign exchange fluctuations. Rising operating expenses and a weak operating margin are other major concerns." (10/30/2017)
  • 2. Needham & Company LLC analysts commented, "RMD’s revenue beat consensus and its EPS met consensus in F1Q18. Organic revenue growth improved to 10% in F1Q18 from 8% in F4Q17 as RMD saw both stronger mask and flow generator growth. RMD’s gross margin met our estimate but was offset by higher than expected SG&A and this caused RMD’s operating margin to miss our estimate. While RMD’s revenue growth was very strong, its EPS growth once again lagged which is consistent with RMD’s performance in recent years. We maintain our Underperform rating since we believe that RMD’s longer-run EPS growth is lower than its large-cap peers (despite its higher revenue growth) and its multiple is at a premium (CY17E P/E of 27.1x vs. large-cap med tech peers at 25.5x)." (10/27/2017)

Who are some of ResMed's key competitors?

Who are ResMed's key executives?

ResMed's management team includes the folowing people:

  • Peter C. Farrell Ph.D., Non-Executive Chairman of the Board, Founder (Age 75)
  • Rob Douglas, President, Chief Operating Officer (Age 57)
  • Michael Farrell, Chief Executive Officer, Director (Age 45)
  • Brett A. Sandercock, Chief Financial Officer (Age 50)
  • Jim Hollingshead Ph.D., President – Sleep Business (Age 54)
  • Richard McHale, President – Respiratory Care (Age 53)
  • Raj Sodhi, President – Software as a Service (SaaS) Business and Chief Technology Officer (Age 44)
  • David Pendarvis, Chief Administrative Officer, Global General Counsel, Company Secretary (Age 57)
  • Ronald R. Taylor, Lead Independent Director (Age 69)
  • Karen Drexler, Director (Age 56)

Who owns ResMed stock?

ResMed's stock is owned by a number of of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (3.46%), Commonwealth Bank of Australia (1.39%), Bank of New York Mellon Corp (1.23%), Legal & General Group Plc (0.54%), Schwab Charles Investment Management Inc. (0.47%) and American Capital Management Inc. (0.46%). Company insiders that own ResMed stock include Anne Reiser, Brett Sandercock, Christopher G Roberts, David Pendarvis, Franz Kozich, Gary W Pace, James Hollingshead, John P Wareham, Jr Gregor K Emmert, Michael J Farrell, Peter C Farrell, Richard Sulpizio, Robert Andrew Douglas, Ronald R Taylor and Warren Russell Hawkins. View Institutional Ownership Trends for ResMed.

Who sold ResMed stock? Who is selling ResMed stock?

ResMed's stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Schroder Investment Management Group, Principal Financial Group Inc., Ameriprise Financial Inc., American International Group Inc., APG Asset Management N.V., Nationwide Fund Advisors and Retirement Systems of Alabama. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, Christopher G Roberts, David Pendarvis, Gary W Pace, James Hollingshead, John P Wareham, Peter C Farrell and Richard Sulpizio. View Insider Buying and Selling for ResMed.

Who bought ResMed stock? Who is buying ResMed stock?

ResMed's stock was acquired by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc., Chevy Chase Trust Holdings Inc., FNY Partners Fund LP, Crossmark Global Holdings Inc., Canada Pension Plan Investment Board, Wells Fargo & Company MN, Dimensional Fund Advisors LP and Prudential Financial Inc.. Company insiders that have bought ResMed stock in the last two years include Franz Kozich, Jr Gregor K Emmert, Ronald R Taylor and Warren Russell Hawkins. View Insider Buying and Selling for ResMed.

How do I buy ResMed stock?

Shares of ResMed can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ResMed's stock price today?

One share of ResMed stock can currently be purchased for approximately $85.84.

How big of a company is ResMed?

ResMed has a market capitalization of $12.26 billion and generates $2.07 billion in revenue each year. The medical equipment provider earns $342.28 million in net income (profit) each year or $2.47 on an earnings per share basis. ResMed employs 6,080 workers across the globe.

How can I contact ResMed?

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at 858-836-5000 or via email at [email protected]

MarketBeat Community Rating for ResMed (RMD)

Community Ranking:  1.6 out of 5 (star)
Outperform Votes:  195 (Vote Outperform)
Underperform Votes:  425 (Vote Underperform)
Total Votes:  620
MarketBeat's community ratings are surveys of what our community members think about ResMed and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ResMed (NYSE:RMD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 1.911.911.851.92
Ratings Breakdown: 4 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
6 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $66.71$65.57$61.88$60.75
Price Target Upside: 22.82% downside22.33% downside21.50% downside10.57% downside

ResMed (NYSE:RMD) Consensus Price Target History

Price Target History for ResMed (NYSE:RMD)

ResMed (NYSE:RMD) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/12/2017BMO Capital MarketsBoost Price TargetMarket Perform$82.00LowView Rating Details
10/30/2017J P Morgan Chase & CoBoost Price TargetOverweight$72.00 -> $73.00N/AView Rating Details
10/27/2017BarclaysBoost Price TargetUnderweight$68.00 -> $70.00N/AView Rating Details
10/27/2017Northland SecuritiesReiterated RatingSell$55.00N/AView Rating Details
10/27/2017Needham & Company LLCReiterated RatingSellN/AView Rating Details
10/12/2017Jefferies GroupReiterated RatingSell$56.00N/AView Rating Details
8/8/2017Credit Suisse GroupDowngradeOutperform -> NeutralLowView Rating Details
8/2/2017CitigroupUpgradeNeutral -> BuyHighView Rating Details
8/2/2017Bank of AmericaDowngradeBuy -> NeutralHighView Rating Details
4/13/2017William BlairReiterated RatingOutperformLowView Rating Details
2/6/2017Canaccord GenuityReiterated RatingHold$59.00N/AView Rating Details
4/27/2016MacquarieUpgradeUnderperform -> NeutralN/AView Rating Details
4/27/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$65.00 -> $57.00N/AView Rating Details
(Data available from 12/13/2015 forward)


ResMed (NYSE:RMD) Earnings History and Estimates Chart

Earnings by Quarter for ResMed (NYSE:RMD)

ResMed (NYSE RMD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/22/2018$0.78N/AView Earnings Details
10/26/2017Q1 2018$0.66$0.66$506.08 million$523.66 millionViewN/AView Earnings Details
8/1/2017Q4 2017$0.75$0.77$557.68 million$556.69 millionViewListenView Earnings Details
4/27/2017Q3 2017$0.70$0.71$525.84 million$514.20 millionViewN/AView Earnings Details
1/23/2017Q217$0.70$0.73$518.60 million$530.40 millionViewN/AView Earnings Details
10/25/2016Q117$0.64$0.62$475.05 million$465.45 millionViewListenView Earnings Details
7/28/2016Q416$0.74$0.74$512.37 million$518.60 millionViewListenView Earnings Details
4/26/2016Q316$0.69$0.68$455.32 million$453.90 millionViewListenView Earnings Details
1/21/2016Q216$0.66$0.69$445.46 million$454.54 millionViewListenView Earnings Details
10/22/2015Q116$0.59$0.58$406.26 million$411.70 millionViewListenView Earnings Details
7/30/2015Q415$0.65$0.68$436.27 million$453.10 millionViewListenView Earnings Details
4/23/2015Q315$0.65$0.65$425.76 million$422.50 millionViewListenView Earnings Details
1/22/2015Q215$0.62$0.64$408.20 million$423.00 millionViewListenView Earnings Details
10/23/2014Q115$0.58$0.58$375.00 million$380.40 millionViewListenView Earnings Details
7/31/2014Q414$0.66$0.64$433.42 million$415.20 millionViewListenView Earnings Details
4/23/2014Q314$0.64$0.63$401.00 million$397.80 millionViewListenView Earnings Details
1/23/2014Q214$0.63$0.60$398.09 million$384.30 millionViewListenView Earnings Details
10/24/2013Q114$0.58$0.56$372.28 million$357.66 millionViewListenView Earnings Details
8/1/2013Q4 2013$0.62$0.62$410.89 million$414.60 millionViewListenView Earnings Details
4/25/2013Q3 2013$0.58$0.58$386.76 million$383.60 millionViewListenView Earnings Details
1/24/2013Q2 2013$0.51$0.53$363.76 million$376.50 millionViewListenView Earnings Details
10/25/2012$0.46$0.49ViewN/AView Earnings Details
8/2/2012$0.49$0.53ViewN/AView Earnings Details
4/26/2012$0.41$0.44ViewN/AView Earnings Details
1/26/2012$0.38$0.42ViewN/AView Earnings Details
10/24/2011$0.35$0.33ViewN/AView Earnings Details
8/4/2011$0.37$0.37ViewN/AView Earnings Details
4/28/2011$0.35$0.35ViewN/AView Earnings Details
1/27/2011$0.36$0.37ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


ResMed (NYSE:RMD) Earnings Estimates

2017 EPS Consensus Estimate: $2.71
2018 EPS Consensus Estimate: $2.94
2019 EPS Consensus Estimate: $2.57
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.57$0.64$0.61
Q2 20173$0.69$0.70$0.69
Q3 20173$0.65$0.70$0.68
Q4 20173$0.70$0.76$0.73
Q1 20182$0.63$0.65$0.64
Q2 20182$0.74$0.77$0.76
Q3 20182$0.72$0.75$0.74
Q4 20182$0.77$0.84$0.81
Q1 20191$0.73$0.73$0.73
Q2 20191$0.84$0.84$0.84
Q3 20191$0.81$0.81$0.81
Q4 20191$0.19$0.19$0.19
(Data provided by Zacks Investment Research)


ResMed (NYSE:RMD) Dividend Information

Next Dividend:12/14/2017
Annual Dividend:$1.40
Dividend Yield:1.63%
Dividend Growth:14.50% (3 Year Average)
Payout Ratio:56.68% (Trailing 12 Months of Earnings)
46.67% (Based on This Year's Estimates)
41.79% (Based on Next Year's Estimates)
Frequency:Quarterly Dividend
Dividend Payments by Quarter for ResMed (NYSE:RMD)

ResMed (NYSE:RMD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

ResMed (NYSE RMD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.77%
Institutional Ownership Percentage: 62.02%
Insider Trades by Quarter for ResMed (NYSE:RMD)
Institutional Ownership by Quarter for ResMed (NYSE:RMD)

ResMed (NYSE RMD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/4/2017David PendarvisInsiderSell2,804$84.17$236,012.68View SEC Filing  
12/1/2017Brett SandercockCFOSell1,250$85.36$106,700.00View SEC Filing  
11/20/2017James HollingsheadInsiderSell7,019$84.16$590,719.04View SEC Filing  
11/9/2017Peter C FarrellDirectorSell118,392$82.70$9,791,018.40View SEC Filing  
11/6/2017Peter C FarrellDirectorSell20,000$83.53$1,670,600.00View SEC Filing  
11/3/2017David PendarvisInsiderSell6,364$82.20$523,120.80View SEC Filing  
11/1/2017Brett SandercockCFOSell1,250$84.50$105,625.00View SEC Filing  
10/4/2017Peter C FarrellDirectorSell20,000$77.01$1,540,200.00View SEC Filing  
10/3/2017David PendarvisInsiderSell6,364$76.94$489,646.16View SEC Filing  
10/2/2017Brett SandercockCFOSell1,250$77.05$96,312.50View SEC Filing  
9/5/2017David PendarvisInsiderSell6,364$77.21$491,364.44View SEC Filing  
9/5/2017Peter C FarrellDirectorSell20,000$76.74$1,534,800.00View SEC Filing  
9/1/2017Brett SandercockCFOSell1,250$77.56$96,950.00View SEC Filing  
8/9/2017Richard SulpizioDirectorSell24,390$73.85$1,801,201.50View SEC Filing  
8/4/2017Peter C FarrellDirectorSell20,000$75.15$1,503,000.00View SEC Filing  
8/3/2017David PendarvisInsiderSell6,364$72.10$458,844.40View SEC Filing  
8/1/2017Brett SandercockCFOSell1,250$77.49$96,862.50View SEC Filing  
7/14/2017James HollingsheadInsiderSell7,140$77.43$552,850.20View SEC Filing  
7/5/2017Peter C FarrellDirectorSell20,000$76.50$1,530,000.00View SEC Filing  
7/3/2017Brett SandercockCFOSell1,250$77.44$96,800.00View SEC Filing  
7/3/2017David PendarvisInsiderSell6,364$77.36$492,319.04View SEC Filing  
6/29/2017Jr. Gregor K EmmertInsiderBuy282,000$0.07$19,740.00
6/28/2017Jr. Gregor K EmmertInsiderBuy424,000$0.06$25,440.00
6/22/2017Richard SulpizioDirectorSell65,887$77.82$5,127,326.34View SEC Filing  
6/15/2017Gary W PaceDirectorSell24,390$76.00$1,853,640.00View SEC Filing  
6/5/2017David PendarvisInsiderSell6,365$72.62$462,226.30View SEC Filing  
6/5/2017Peter C FarrellDirectorSell20,000$72.65$1,453,000.00View SEC Filing  
6/1/2017Brett SandercockCFOSell1,250$71.02$88,775.00View SEC Filing  
5/4/2017Peter C FarrellDirectorSell20,000$68.75$1,375,000.00View SEC Filing  
5/3/2017David PendarvisInsiderSell6,365$69.55$442,685.75View SEC Filing  
5/1/2017Brett SandercockCFOSell1,250$68.60$85,750.00View SEC Filing  
4/17/2017James HollingsheadInsiderSell7,139$68.37$488,093.43View SEC Filing  
4/4/2017Peter C FarrellDirectorSell20,000$70.67$1,413,400.00View SEC Filing  
4/3/2017Brett SandercockCFOSell1,250$71.65$89,562.50View SEC Filing  
4/3/2017David PendarvisInsiderSell6,365$71.59$455,670.35View SEC Filing  
3/1/2017Brett SandercockCFOSell1,250$72.48$90,600.00View SEC Filing  
2/24/2017John P WarehamDirectorSell28,403$71.77$2,038,483.31View SEC Filing  
2/20/2017Christopher G RobertsDirectorSell10,000$71.91$719,100.00View SEC Filing  
2/15/2017Franz KozichDirectorBuy50,000$0.05$2,500.00
2/14/2017Warren Russell HawkinsDirectorBuy60,000$0.05$3,000.00
2/6/2017Peter C FarrellDirectorSell20,000$68.32$1,366,400.00View SEC Filing  
2/3/2017David PendarvisInsiderSell6,365$67.16$427,473.40View SEC Filing  
1/17/2017James HollingsheadInsiderSell7,084$64.44$456,492.96View SEC Filing  
1/4/2017Peter C FarrellDirectorSell20,000$62.14$1,242,800.00View SEC Filing  
1/3/2017David PendarvisInsiderSell6,365$61.95$394,311.75View SEC Filing  
12/5/2016David PendarvisInsiderSell6,365$60.00$381,900.00View SEC Filing  
12/5/2016Peter C FarrellDirectorSell20,000$59.83$1,196,600.00View SEC Filing  
11/4/2016Peter C FarrellDirectorSell20,000$57.28$1,145,600.00View SEC Filing  
11/3/2016David PendarvisInsiderSell6,033$57.79$348,647.07View SEC Filing  
10/18/2016James HollingsheadInsiderSell1,967$64.71$127,284.57View SEC Filing  
10/17/2016James HollingsheadInsiderSell5,264$64.43$339,159.52View SEC Filing  
10/17/2016Michael J FarrellCEOSell5,975$64.25$383,893.75View SEC Filing  
10/4/2016Peter C FarrellDirectorSell20,000$64.70$1,294,000.00View SEC Filing  
10/3/2016David PendarvisInsiderSell6,000$63.95$383,700.00View SEC Filing  
9/15/2016Michael J. FarrellCEOSell5,975$64.84$387,419.00View SEC Filing  
9/6/2016David PendarvisInsiderSell6,000$67.18$403,080.00View SEC Filing  
9/6/2016Peter C FarrellDirectorSell20,000$67.29$1,345,800.00View SEC Filing  
8/19/2016Gary W PaceDirectorSell36,000$69.93$2,517,480.00View SEC Filing  
8/17/2016Ronald R TaylorDirectorBuy2,487$69.13$171,926.31View SEC Filing  
8/16/2016Ronald R TaylorDirectorSell23,102$69.25$1,599,813.50View SEC Filing  
8/15/2016Michael J. FarrellCEOSell5,975$70.41$420,699.75View SEC Filing  
8/11/2016Brett SandercockCFOSell35,000$70.50$2,467,500.00View SEC Filing  
8/10/2016Richard SulpizioDirectorSell36,000$70.15$2,525,400.00View SEC Filing  
8/8/2016John P WarehamDirectorSell24,390$70.32$1,715,104.80View SEC Filing  
8/4/2016Peter C FarrellDirectorSell20,000$69.16$1,383,200.00View SEC Filing  
8/3/2016David PendarvisInsiderSell6,000$68.86$413,160.00View SEC Filing  
7/15/2016Michael J FarrellCEOSell5,975$65.03$388,554.25View SEC Filing  
7/14/2016James HollingsheadInsiderSell2,753$65.02$179,000.06View SEC Filing  
7/7/2016Peter C FarrellDirectorSell20,000$63.62$1,272,400.00View SEC Filing  
7/5/2016David PendarvisInsiderSell6,000$63.62$381,720.00View SEC Filing  
6/15/2016James HollingsheadInsiderSell4,458$59.40$264,805.20View SEC Filing  
6/15/2016Michael J FarrellCEOSell5,975$59.63$356,289.25View SEC Filing  
6/6/2016Peter C FarrellDirectorSell20,000$59.82$1,196,400.00View SEC Filing  
6/3/2016David PendarvisInsiderSell6,000$59.41$356,460.00View SEC Filing  
5/16/2016Michael J FarrellCEOSell5,975$57.64$344,399.00View SEC Filing  
5/4/2016Peter C FarrellDirectorSell20,000$55.90$1,118,000.00View SEC Filing  
5/3/2016David PendarvisInsiderSell6,000$56.02$336,120.00View SEC Filing  
4/15/2016Michael J FarrellCEOSell5,975$59.34$354,556.50View SEC Filing  
4/4/2016David PendarvisInsiderSell6,000$58.70$352,200.00View SEC Filing  
4/4/2016Peter C FarrellDirectorSell20,000$57.51$1,150,200.00View SEC Filing  
3/15/2016James HollingsheadInsiderSell4,500$58.57$263,565.00View SEC Filing  
3/15/2016Michael J FarrellCEOSell5,975$58.57$349,955.75View SEC Filing  
3/11/2016Gary W PaceDirectorSell36,000$60.00$2,160,000.00View SEC Filing  
3/4/2016Peter C FarrellDirectorSell20,000$57.51$1,150,200.00View SEC Filing  
3/3/2016David PendarvisInsiderSell6,000$57.26$343,560.00View SEC Filing  
2/29/2016Anne ReiserInsiderSell1,946$57.06$111,038.76View SEC Filing  
2/26/2016Brett SandercockCFOSell30,000$57.61$1,728,300.00View SEC Filing  
2/26/2016Richard SulpizioDirectorSell36,000$57.88$2,083,680.00View SEC Filing  
2/25/2016Peter C FarrellDirectorSell139,980$57.31$8,022,253.80View SEC Filing  
2/16/2016Michael J. FarrellCEOSell5,975$58.20$347,745.00View SEC Filing  
2/4/2016Peter C. FarrellDirectorSell20,000$57.70$1,154,000.00View SEC Filing  
2/3/2016David PendarvisinsiderSell6,000$57.43$344,580.00View SEC Filing  
1/27/2016Franz KozichDirectorBuy60,000$0.04$2,100.00
1/15/2016Michael J. FarrellCEOSell5,975$53.07$317,093.25View SEC Filing  
1/4/2016David PendarvisinsiderSell6,000$52.16$312,960.00View SEC Filing  
1/4/2016Peter C. FarrellDirectorSell20,000$52.22$1,044,400.00View SEC Filing  
1/4/2016Robert Andrew DouglasCOOSell6,337$52.97$335,670.89View SEC Filing  
12/15/2015James HollingsheadInsiderSell4,500$55.95$251,775.00View SEC Filing  
12/3/2015David PendarvisinsiderSell6,000$59.38$356,280.00View SEC Filing  
12/1/2015Robert Andrew DouglasCOOSell6,333$59.77$378,523.41View SEC Filing  
11/25/2015Warren Russell HawkinsDirectorBuy15,000$0.06$825.00
11/24/2015Warren Russell HawkinsDirectorBuy3,000$0.06$165.00
11/20/2015Christopher G RobertsDirectorSell12,000$59.03$708,360.00View SEC Filing  
11/16/2015Michael J. FarrellCEOSell5,975$57.03$340,754.25View SEC Filing  
11/12/2015Donald DarkininsiderSell25,442$57.72$1,468,512.24View SEC Filing  
11/2/2015Robert Andrew DouglasCOOSell6,333$57.60$364,780.80View SEC Filing  
10/27/2015Anne ReiserinsiderSell3,000$57.01$171,030.00View SEC Filing  
10/15/2015Michael J. FarrellCEOSell5,975$55.35$330,716.25View SEC Filing  
10/5/2015David PendarvisinsiderSell5,500$52.47$288,585.00View SEC Filing  
10/5/2015Robert Andrew DouglasCOOSell6,333$52.13$330,139.29View SEC Filing  
10/1/2015Peter C. FarrellChairmanSell27,169$50.93$1,383,717.17View SEC Filing  
9/15/2015James HollingsheadInsiderSell4,455$50.67$225,734.85View SEC Filing  
9/15/2015Michael J. FarrellCEOSell5,975$50.89$304,067.75View SEC Filing  
9/3/2015David PendarvisinsiderSell5,500$51.78$284,790.00View SEC Filing  
9/3/2015Robert Andrew DouglasCOOSell6,333$52.04$329,569.32View SEC Filing  
9/1/2015Peter C. FarrellChairmanSell36,000$50.82$1,829,520.00View SEC Filing  
8/28/2015Anne ReiserinsiderSell6,000$52.26$313,560.00View SEC Filing  
8/27/2015Richard SulpizioDirectorSell10,860$51.83$562,873.80View SEC Filing  
8/17/2015Michael J FarrellCEOSell5,975$55.54$331,851.50View SEC Filing  
7/15/2015Michael J FarrellCEOSell5,975$57.59$344,100.25View SEC Filing  
7/6/2015David PendarvisInsiderSell5,500$55.19$303,545.00View SEC Filing  
7/1/2015Peter C FarrellChairmanSell36,000$55.61$2,001,960.00View SEC Filing  
7/1/2015Robert Andrew DouglasCOOSell6,333$56.59$358,384.47View SEC Filing  
6/15/2015Michael J FarrellCEOSell5,975$57.87$345,773.25View SEC Filing  
6/3/2015David PendarvisInsiderSell5,500$59.41$326,755.00View SEC Filing  
6/1/2015Peter C FarrellChairmanSell36,000$59.25$2,133,000.00View SEC Filing  
6/1/2015Robert Andrew DouglasCOOSell6,333$59.22$375,040.26View SEC Filing  
5/4/2015David PendarvisInsiderSell5,500$65.10$358,050.00View SEC Filing  
4/6/2015David PendarvisInsiderSell5,500$72.60$399,300.00View SEC Filing  
4/1/2015Peter C FarrellChairmanSell36,000$70.70$2,545,200.00View SEC Filing  
4/1/2015Robert Andrew DouglasCOOSell6,333$70.67$447,553.11View SEC Filing  
3/27/2015Warren Russell HawkinsDirectorBuy10,000$0.09$900.00
3/26/2015Warren Russell HawkinsDirectorBuy10,000$0.08$800.00
3/16/2015Anne ReiserInsiderSell4,000$69.10$276,400.00View SEC Filing  
3/16/2015Michael J FarrellCEOSell5,975$69.10$412,872.50View SEC Filing  
3/9/2015Anne ReiserInsiderSell3,000$66.75$200,250.00View SEC Filing  
3/2/2015Peter C FarrellChairmanSell36,000$64.64$2,327,040.00View SEC Filing  
3/2/2015Robert Andrew DouglasCOOSell6,333$64.39$407,781.87View SEC Filing  
2/17/2015Anne ReiserInsiderSell5,000$66.11$330,550.00View SEC Filing  
2/5/2015David PendarvisInsiderSell5,500$62.35$342,925.00View SEC Filing  
2/4/2015John P WarehamDirectorSell36,000$63.49$2,285,640.00View SEC Filing  
2/3/2015Brett SandercockCFOSell18,670$62.82$1,172,849.40View SEC Filing  
2/3/2015Robert Andrew DouglasCOOSell6,333$62.35$394,862.55View SEC Filing  
2/2/2015Peter C FarrellChairmanSell36,000$61.97$2,230,920.00View SEC Filing  
1/26/2015Gary W PaceDirectorSell48,000$66.77$3,204,960.00View SEC Filing  
1/5/2015David PendarvisInsiderSell5,500$57.09$313,995.00View SEC Filing  
1/2/2015Peter C FarrellChairmanSell36,000$56.99$2,051,640.00View SEC Filing  
1/2/2015Robert Andrew DouglasCOOSell8,000$56.99$455,920.00View SEC Filing  
12/1/2014Peter C FarrellChairmanSell36,000$53.28$1,918,080.00View SEC Filing  
12/1/2014Robert Andrew DouglasCOOSell8,000$52.93$423,440.00View SEC Filing  
11/18/2014Peter C FarrellChairmanSell36,000$52.39$1,886,040.00View SEC Filing  
11/3/2014David PendarvisInsiderSell3,557$52.00$184,964.00View SEC Filing  
11/3/2014Robert Andrew DouglasCOOSell8,000$51.84$414,720.00View SEC Filing  
10/29/2014Peter C FarrellChairmanSell119,204$51.84$6,179,535.36View SEC Filing  
10/3/2014David PendarvisInsiderSell5,000$49.84$249,200.00View SEC Filing  
10/1/2014Robert Andrew DouglasCOOSell8,000$49.11$392,880.00View SEC Filing  
9/15/2014Michael J FarrellCEOSell3,200$52.41$167,712.00View SEC Filing  
9/5/2014Brett SandercockCFOSell10,000$52.99$529,900.00View SEC Filing  
9/3/2014Brett SandercockCFOSell10,000$53.23$532,300.00View SEC Filing  
9/3/2014David PendarvisInsiderSell5,000$53.23$266,150.00View SEC Filing  
8/22/2014Anne ReiserInsiderSell3,000$53.37$160,110.00View SEC Filing  
8/4/2014David PendarvisInsiderSell5,000$49.12$245,600.00View SEC Filing  
8/1/2014Peter C FarrellDirectorSell25,000$49.04$1,226,000.00View SEC Filing  
8/1/2014Robert Andrew DouglasCOOSell8,000$48.95$391,600.00View SEC Filing  
7/15/2014Michael J FarrellCEOSell3,200$49.22$157,504.00View SEC Filing  
7/3/2014David PendarvisInsiderSell5,000$50.04$250,200.00View SEC Filing  
7/1/2014Peter C FarrellDirectorSell25,000$50.09$1,252,250.00View SEC Filing  
7/1/2014Robert Andrew DouglasCOOSell8,000$50.11$400,880.00View SEC Filing  
6/16/2014Michael J FarrellCEOSell3,200$53.20$170,240.00View SEC Filing  
6/3/2014David PendarvisInsiderSell5,000$49.76$248,800.00View SEC Filing  
6/2/2014Peter C FarrellDirectorSell25,000$49.57$1,239,250.00View SEC Filing  
6/2/2014Robert Andrew DouglasCOOSell8,000$50.11$400,880.00View SEC Filing  
5/29/2014Christopher G RobertsDirectorSell25,000$49.73$1,243,250.00View SEC Filing  
5/15/2014Michael FarrellCEOSell3,700$50.54$186,998.00View SEC Filing  
5/13/2014John WarehamDirectorSell18,000$51.00$918,000.00View SEC Filing  
5/8/2014Brett SandercockCFOSell5,000$50.00$250,000.00View SEC Filing  
5/6/2014Brett SandercockCFOSell4,290$50.00$214,500.00View SEC Filing  
5/1/2014Peter FarrellDirectorSell25,000$49.80$1,245,000.00View SEC Filing  
5/1/2014Robert Andrew DouglasCOOSell8,000$49.75$398,000.00View SEC Filing  
4/29/2014David PendarvisInsiderSell15,000$50.01$750,150.00View SEC Filing  
4/21/2014Peter FarrellDirectorSell75,000$48.01$3,600,750.00View SEC Filing  
4/4/2014David PendarvisInsiderSell5,000$44.95$224,750.00View SEC Filing  
2/12/2014Brett SandercockCFOSell10,687$46.00$491,602.00View SEC Filing  
1/9/2014Peter FarrellDirectorSell25,000$48.00$1,200,000.00View SEC Filing  
12/2/2013Robert Andrew DouglasCOOSell8,000$49.10$392,800.00View SEC Filing  
11/20/2013Brett SandercockCFOSell15,000$51.06$765,900.00View SEC Filing  
11/20/2013James HollingsheadInsiderSell4,000$51.24$204,960.00View SEC Filing  
11/12/2013Donald DarkinInsiderSell31,063$50.04$1,554,392.52View SEC Filing  
10/29/2013David PendarvisInsiderSell37,744$50.42$1,903,052.48View SEC Filing  
10/1/2013Peter C FarrellDirectorSell25,000$53.21$1,330,250.00View SEC Filing  
10/1/2013Robert Andrew DouglasCOOSell8,000$53.20$425,600.00View SEC Filing  
9/9/2013Gary W PaceDirectorSell12,000$50.05$600,600.00View SEC Filing  
9/5/2013Peter C FarrellDirectorSell25,000$48.00$1,200,000.00View SEC Filing  
9/3/2013Robert Andrew DouglasCOOSell8,000$47.51$380,080.00View SEC Filing  
8/28/2013Michael QuinnDirectorSell48,000$48.34$2,320,320.00View SEC Filing  
8/27/2013Brett SandercockCFOSell5,000$49.00$245,000.00View SEC Filing  
8/26/2013Christopher RobertsDirectorSell10,000$49.49$494,900.00View SEC Filing  
8/1/2013Robert Andrew DouglasCOOSell8,000$48.57$388,560.00View SEC Filing  
6/3/2013Robert Andrew DouglasCOOSell8,000$47.96$383,680.00View SEC Filing  
5/24/2013Christopher G RobertsDirectorSell20,000$49.45$989,000.00View SEC Filing  
5/22/2013John P WarehamDirectorSell18,000$50.20$903,600.00View SEC Filing  
5/13/2013Michael A QuinnDirectorSell15,000$50.94$764,100.00View SEC Filing  
5/8/2013Brett SandercockCFOSell28,000$48.97$1,371,160.00View SEC Filing  
2/4/2013Robert Andrew DouglasCOOSell8,000$44.14$353,120.00View SEC Filing  
8/8/2012Michael J FarrellInsiderSell30,000$35.58$1,067,400.00View SEC Filing  
(Data available from 1/1/2013 forward)


ResMed (NYSE RMD) News Headlines

BMO Capital Markets Raises ResMed (RMD) Price Target to $82.00BMO Capital Markets Raises ResMed (RMD) Price Target to $82.00 - December 12 at 11:28 AM
Why the ResMed Inc. (CHESS) share price is falling todayWhy the ResMed Inc. (CHESS) share price is falling today - December 12 at 8:43 AM
$577.00 Million in Sales Expected for ResMed Inc. (RMD) This Quarter$577.00 Million in Sales Expected for ResMed Inc. (RMD) This Quarter - December 10 at 8:58 AM
 Brokerages Expect ResMed Inc. (RMD) to Post $0.76 EPS Brokerages Expect ResMed Inc. (RMD) to Post $0.76 EPS - December 8 at 9:36 AM
ResMed Inc. (RMD) Insider Sells $236,012.68 in StockResMed Inc. (RMD) Insider Sells $236,012.68 in Stock - December 5 at 6:48 PM
ResMed Inc. (RMD) CFO Brett Sandercock Sells 1,250 SharesResMed Inc. (RMD) CFO Brett Sandercock Sells 1,250 Shares - December 4 at 7:00 PM
ResMed (RMD) Rides on Innovation Amid Reimbursement Woes - NasdaqResMed (RMD) Rides on Innovation Amid Reimbursement Woes - Nasdaq - December 3 at 8:01 AM
Morgans unveils its “high conviction” stock picks for 2018Morgans unveils its “high conviction” stock picks for 2018 - December 1 at 10:49 AM
Detailed Research: Economic Perspectives on Cimarex Energy, Las Vegas Sands, Echelon, ResMed, Qorvo, and Integrated Device Technology — What Drives Growth in Todays Competitive LandscapeDetailed Research: Economic Perspectives on Cimarex Energy, Las Vegas Sands, Echelon, ResMed, Qorvo, and Integrated Device Technology — What Drives Growth in Today's Competitive Landscape - December 1 at 10:49 AM
ResMed (RMD) Rides on Innovation Amid Reimbursement WoesResMed (RMD) Rides on Innovation Amid Reimbursement Woes - December 1 at 10:49 AM
Free Post Earnings Research Report: ResMed’s Revenue and EPS Jumped 13% Y-O-YFree Post Earnings Research Report: ResMed’s Revenue and EPS Jumped 13% Y-O-Y - November 30 at 8:41 AM
Why Is ResMed (RMD) Up 8.4% Since the Last Earnings Report?Why Is ResMed (RMD) Up 8.4% Since the Last Earnings Report? - November 29 at 8:39 AM
ETFs with exposure to ResMed, Inc. : November 27, 2017ETFs with exposure to ResMed, Inc. : November 27, 2017 - November 27 at 4:22 PM
ResMed Inc. (RMD) Receives Average Rating of "Hold" from BrokeragesResMed Inc. (RMD) Receives Average Rating of "Hold" from Brokerages - November 26 at 6:14 PM
James Hollingshead Sells 7,019 Shares of ResMed Inc. (RMD) StockJames Hollingshead Sells 7,019 Shares of ResMed Inc. (RMD) Stock - November 22 at 1:40 PM
Zacks: Analysts Anticipate ResMed Inc. (RMD) to Post $0.76 EPSZacks: Analysts Anticipate ResMed Inc. (RMD) to Post $0.76 EPS - November 20 at 1:38 PM
ResMed Elects Karen Drexler to Its Board of DirectorsResMed Elects Karen Drexler to Its Board of Directors - November 18 at 11:26 AM
Statement by ResMed on United Kingdom Case with Fisher & PaykelStatement by ResMed on United Kingdom Case with Fisher & Paykel - November 14 at 7:23 AM
ETFs with exposure to ResMed, Inc. : November 13, 2017ETFs with exposure to ResMed, Inc. : November 13, 2017 - November 14 at 7:23 AM
ResMed Inc. (RMD) Director Peter C. Farrell Sells 118,392 SharesResMed Inc. (RMD) Director Peter C. Farrell Sells 118,392 Shares - November 13 at 6:04 PM
SleepScore Labs Launches the Worlds Most Advanced Sleep Improvement SystemSleepScore Labs Launches the World's Most Advanced Sleep Improvement System - November 12 at 12:21 PM
Insider Selling: ResMed Inc. (RMD) Director Sells 20,000 Shares of StockInsider Selling: ResMed Inc. (RMD) Director Sells 20,000 Shares of Stock - November 8 at 6:32 PM
ResMed (RMD) Ranking Raised to Buy on Robust Quant ScoreResMed (RMD) Ranking Raised to Buy on Robust Quant Score - November 7 at 5:35 PM
Insider Selling: ResMed Inc. (RMD) Insider Sells 6,364 Shares of StockInsider Selling: ResMed Inc. (RMD) Insider Sells 6,364 Shares of Stock - November 6 at 3:34 PM
ResMed (RMD) vs. Its Rivals Head to Head SurveyResMed (RMD) vs. Its Rivals Head to Head Survey - November 5 at 9:24 AM
ETFs with exposure to ResMed, Inc. : November 2, 2017ETFs with exposure to ResMed, Inc. : November 2, 2017 - November 4 at 11:55 AM
Read This Before Buying ResMed Inc (RMD) For Its Upcoming $0.35 DividendRead This Before Buying ResMed Inc (RMD) For Its Upcoming $0.35 Dividend - November 4 at 11:55 AM
ResMed Inc. (RMD) CFO Sells $105,625.00 in StockResMed Inc. (RMD) CFO Sells $105,625.00 in Stock - November 2 at 8:54 PM
Head-To-Head Analysis: ResMed (RMD) & Its CompetitorsHead-To-Head Analysis: ResMed (RMD) & Its Competitors - November 2 at 2:04 PM
ResMed Inc. (RMD) Expected to Post Quarterly Sales of $577.00 MillionResMed Inc. (RMD) Expected to Post Quarterly Sales of $577.00 Million - November 2 at 12:18 PM
ResMed, Inc. :RMD-US: Earnings Analysis: Q1, 2018 By the Numbers : November 1, 2017ResMed, Inc. :RMD-US: Earnings Analysis: Q1, 2018 By the Numbers : November 1, 2017 - November 2 at 8:25 AM
ResMed Inc. (RMD) Receives Consensus Recommendation of "Hold" from AnalystsResMed Inc. (RMD) Receives Consensus Recommendation of "Hold" from Analysts - November 1 at 5:32 PM
ResMed's Sales and Profits RiseResMed's Sales and Profits Rise - October 31 at 8:46 AM
$0.76 EPS Expected for ResMed Inc. (RMD) This Quarter$0.76 EPS Expected for ResMed Inc. (RMD) This Quarter - October 31 at 3:18 AM
ResMed Inc. (RMD) Upgraded at Zacks Investment ResearchResMed Inc. (RMD) Upgraded at Zacks Investment Research - October 30 at 2:00 PM
Q2 2018 EPS Estimates for ResMed Inc. (RMD) Reduced by William BlairQ2 2018 EPS Estimates for ResMed Inc. (RMD) Reduced by William Blair - October 30 at 8:56 AM
ResMed Inc. (RMD) Earns "Sell" Rating from Northland SecuritiesResMed Inc. (RMD) Earns "Sell" Rating from Northland Securities - October 28 at 6:46 PM
BMO Capital Markets Raises ResMed Inc. (RMD) Price Target to $74.00BMO Capital Markets Raises ResMed Inc. (RMD) Price Target to $74.00 - October 27 at 9:36 PM
ResMed Inc. (RMD) Price Target Increased to $70.00 by Analysts at Barclays PLCResMed Inc. (RMD) Price Target Increased to $70.00 by Analysts at Barclays PLC - October 27 at 9:36 PM
Heres Why ResMed Inc. Stock Spiked TodayHere's Why ResMed Inc. Stock Spiked Today - October 27 at 4:25 PM
The New #1 Most Shorted S&P 500 Component: ResMed - ForbesThe New #1 Most Shorted S&P 500 Component: ResMed - Forbes - October 27 at 2:48 PM
ResMed (RMD) Q1 Earnings Top on Growth in All Business Lines - NasdaqResMed (RMD) Q1 Earnings Top on Growth in All Business Lines - Nasdaq - October 27 at 2:48 PM
ResMed beats 1Q profit forecastsResMed beats 1Q profit forecasts - October 27 at 2:48 PM
ResMed (RMD) Q1 Earnings Top on Growth in All Business LinesResMed (RMD) Q1 Earnings Top on Growth in All Business Lines - October 27 at 2:48 PM
Edited Transcript of RMD earnings conference call or presentation 26-Oct-17 8:30pm GMTEdited Transcript of RMD earnings conference call or presentation 26-Oct-17 8:30pm GMT - October 27 at 2:48 PM
ResMeds (RMD) "Sell" Rating Reaffirmed at Needham & Company LLCResMed's (RMD) "Sell" Rating Reaffirmed at Needham & Company LLC - October 27 at 7:59 AM
ResMed Inc. (RMD) Releases Quarterly  Earnings Results, Hits ExpectationsResMed Inc. (RMD) Releases Quarterly Earnings Results, Hits Expectations - October 26 at 7:34 PM
ResMed Inc. Announces Quarterly Dividend of $0.35 (RMD)ResMed Inc. Announces Quarterly Dividend of $0.35 (RMD) - October 26 at 6:52 PM
ResMed Inc. (RMD) Rating Lowered to Sell at Zacks Investment ResearchResMed Inc. (RMD) Rating Lowered to Sell at Zacks Investment Research - October 24 at 2:22 PM
Credit Suisse: CSL Limited shares are set to outperformCredit Suisse: CSL Limited shares are set to outperform - October 19 at 8:12 AM

SEC Filings

ResMed (NYSE:RMD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


ResMed (NYSE:RMD) Income Statement, Balance Sheet and Cash Flow Statement


ResMed (NYSE RMD) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.